Lover of animals, glycoscience, and travel 💕
Staff scientist at University of Basel, co-founder of SCS Swiss Women in Chemistry
Proudly 🇨🇦 but settled in 🇨🇭 to escape the humiliation of hating 🥅 🏒
#GlycoTime #Glycobiology #Glycochemistry #ChemTwitter #WomenInSTEM #WomenInScience
| ORCID | 0000-0002-2649-3427 |
| PRONOUNS | She/her 🏳️🌈 |
The European Glycoscience Community (EGC) spring webinar series kicks off tomorrow! 🥳 We will be joined by two great speakers, Prof. Fabian Pfrengle (#BOKU) & Dr. Nitish Verma (#INRS), focused on recent developments in glycochemistry.
Registration and complete spring schedule available at: https://euroglyco.com/egc-webinar/egc-2023-webinar-schedule/
New article by Katharina Ribbeck and coworkers:
Host-derived O-glycans #mucins inhibit toxigenic conversion by a #virulence-encoding #phage in #Vibrio #cholerae
Sneaking in one more publication before the holidays! 🎅🏽🎄
With postdoc Dr. Sateesh Dubbu and Dr. Jampani Santhi, we elaborate on the uses of carbohydrate-based dienes as privileged scaffolds for the synthesis of pharmaceutically-interesting molecules
https://onlinelibrary.wiley.com/doi/abs/10.1002/hlca.202200135
I am super excited to let you know that our paper "Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics" in collaboration with Max Crispin's lab is now live on JMB #glycotime #SarsCoV2 #viralinfection #variants
#tootorial 🧵 ⬇️
https://www.sciencedirect.com/science/article/pii/S0022283622005551#f0030
Join our team!!
Xmas came early in the form of a grant 😁
We are looking to fill TWO postdoc positions in chemoenzymatic and/or carbohydrate synthesis, with a focus on developing new glycan-based antimicrobial therapies.
Positions are available from April 1, 2023, and applications must be submitted via the University of Basel job portal:
The Molecular Pharmacy group at the Department of Pharmaceutical Sciences is focused on early stages of drug discovery, including target identification and validation, the design, screening, characterization and optimization of molecules with drug-like properties, and the development of novel therapeutic concepts. The group follows a highly integrated and multidisciplinary approach, including drug design, compound synthesis and characterization, protein engineering, target preparation, assay development, and interaction analyses.
📜 Our latest collaboration out in @embojournal!
In efforts led by Dr Ben Wang and Dr Julie Takagi, we identify Core 2 glycans as inhibitors of toxigenic conversion by a virulence-encoding phage in Vibrio cholerae.
#GlycoTime
💰 support: @snsf_ch & @UniBasel
https://embopress.org/doi/full/10.15252/embj.2022111562
So exciting to see our #GlycoTime research 🧐 featured in a post by Dr. Matthew D Vandermeulen from the University at Buffalo in his blog "Science with a funguy" (LOVE the name 😂)
I may be biased, but definitely think it's worth checking out! 🙏🏽
https://sciencewithafunguy.com/2022/09/21/fighting-fungal-infections-with-mucus/
The EMBO Journal
Elisa Fadda-🔺
Anne_Imberty